89 related articles for article (PubMed ID: 29077654)
1. Improved Pulse Wave Velocity and Renal Function in Individualized Calcineurin Inhibitor Treatment by Immunomonitoring: The Randomized Controlled Calcineurin Inhibitor-Sparing Trial.
Sommerer C; Brocke J; Bruckner T; Schaier M; Morath C; Meuer S; Zeier M; Giese T
Transplantation; 2018 Mar; 102(3):510-520. PubMed ID: 29077654
[TBL] [Abstract][Full Text] [Related]
2. The Calcineurin Inhibitor-Sparing (CIS) Trial - individualised calcineurin-inhibitor treatment by immunomonitoring in renal allograft recipients: protocol for a randomised controlled trial.
Sommerer C; Schaier M; Morath C; Schwenger V; Rauch G; Giese T; Zeier M
Trials; 2014 Dec; 15():489. PubMed ID: 25494823
[TBL] [Abstract][Full Text] [Related]
3. Monitoring of calcineurin inhibitors by NFAT-regulated gene expression in de novo renal allograft recipients on cyclosporine A.
Sommerer C; Zeier M; Meuer S; Giese T
Clin Nephrol; 2015 Sep; 84(3):165-72. PubMed ID: 26226950
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic monitoring of nuclear factor of activated T cell-regulated gene expression in liver allograft recipients on immunosuppressive therapy with calcineurin inhibitors in the course of time and correlation with acute rejection episodes--a prospective study.
Steinebrunner N; Sandig C; Sommerer C; Hinz U; Giese T; Stremmel W; Zahn A
Ann Transplant; 2014 Jan; 19():32-40. PubMed ID: 24457606
[TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic monitoring of cyclosporin A reveals risk of opportunistic infections and malignancies in renal transplant recipients 65 years and older.
Sommerer C; Schnitzler P; Meuer S; Zeier M; Giese T
Ther Drug Monit; 2011 Dec; 33(6):694-8. PubMed ID: 22105585
[TBL] [Abstract][Full Text] [Related]
6. Reduced residual gene expression of nuclear factor of activated T cells-regulated genes correlates with the risk of cytomegalovirus infection after liver transplantation.
Steinebrunner N; Sandig C; Sommerer C; Hinz U; Giese T; Stremmel W; Zahn A
Transpl Infect Dis; 2014 Jun; 16(3):379-86. PubMed ID: 24666466
[TBL] [Abstract][Full Text] [Related]
7. Immunomonitoring of nuclear factor of activated T cells-regulated gene expression: the first clinical trial in liver allograft recipients.
Zahn A; Schott N; Hinz U; Stremmel W; Schmidt J; Ganten T; Gotthardt D; Meuer S; Zeier M; Giese T; Sommerer C
Liver Transpl; 2011 Apr; 17(4):466-73. PubMed ID: 21445930
[TBL] [Abstract][Full Text] [Related]
8. Nuclear Factor of Activated T Cells-Regulated Gene Expression as Predictive Biomarker of Personal Response to Calcineurin Inhibitors.
Sommerer C; Giese T
Ther Drug Monit; 2016 Apr; 38 Suppl 1():S50-6. PubMed ID: 26418701
[TBL] [Abstract][Full Text] [Related]
9. Analysis of NFAT-regulated gene expression in vivo: a novel perspective for optimal individualized doses of calcineurin inhibitors.
Giese T; Zeier M; Meuer S
Nephrol Dial Transplant; 2004 Jul; 19 Suppl 4():iv55-60. PubMed ID: 15240851
[TBL] [Abstract][Full Text] [Related]
10. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial.
Budde K; Becker T; Arns W; Sommerer C; Reinke P; Eisenberger U; Kramer S; Fischer W; Gschaidmeier H; Pietruck F;
Lancet; 2011 Mar; 377(9768):837-47. PubMed ID: 21334736
[TBL] [Abstract][Full Text] [Related]
11. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression.
Sommerer C; Giese T; Schmidt J; Meuer S; Zeier M
Transplantation; 2008 Jan; 85(1):15-21. PubMed ID: 18192906
[TBL] [Abstract][Full Text] [Related]
12. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation.
Cibrik D; Silva HT; Vathsala A; Lackova E; Cornu-Artis C; Walker RG; Wang Z; Zibari GB; Shihab F; Kim YS
Transplantation; 2013 Apr; 95(7):933-42. PubMed ID: 23422495
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamic immune monitoring of NFAT-regulated genes predicts skin cancer in elderly long-term renal transplant recipients.
Sommerer C; Hartschuh W; Enk A; Meuer S; Zeier M; Giese T
Clin Transplant; 2008; 22(5):549-54. PubMed ID: 18394001
[TBL] [Abstract][Full Text] [Related]
14. Calcineurin inhibitors regulate fibroblast growth factor 23 (FGF23) synthesis.
Bär L; Großmann C; Gekle M; Föller M
Naunyn Schmiedebergs Arch Pharmacol; 2017 Nov; 390(11):1117-1123. PubMed ID: 28761977
[TBL] [Abstract][Full Text] [Related]
15. Analytical Validation and Cross-Validation of an NFAT-Regulated Gene Expression Assay for Pharmacodynamic Monitoring of Therapy With Calcineurin Inhibitors.
Abdel-Kahaar E; Giese T; Sommerer C; Rieger H; Shipkova M; Wieland E
Ther Drug Monit; 2016 Dec; 38(6):711-716. PubMed ID: 27661400
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study.
Lehner F; Budde K; Zeier M; Wüthrich RP; Reinke P; Eisenberger U; Mühlfeld A; Arns W; Stahl R; Heller K; Witzke O; Wolters HH; Suwelack B; Klehr HU; Stangl M; Hauser IA; Nadalin S; Porstner M; May C; Paulus EM; Sommerer C;
Transpl Int; 2014 Nov; 27(11):1192-204. PubMed ID: 25070687
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic monitoring of cyclosporine a in renal allograft recipients shows a quantitative relationship between immunosuppression and the occurrence of recurrent infections and malignancies.
Sommerer C; Konstandin M; Dengler T; Schmidt J; Meuer S; Zeier M; Giese T
Transplantation; 2006 Nov; 82(10):1280-5. PubMed ID: 17130775
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial: switch to combined mycophenolate mofetil and minimal dose calcineurin inhibitor in stable liver transplant patients--assessment of renal and allograft function, cardiovascular risk factors and immune monitoring.
Cicinnati VR; Yu Z; Klein CG; Sotiropoulos GC; Saner F; Malagó M; Frilling A; Gerken G; Broelsch CE; Beckebaum S
Aliment Pharmacol Ther; 2007 Nov; 26(9):1195-208. PubMed ID: 17944734
[TBL] [Abstract][Full Text] [Related]
19. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients.
Seckinger J; Sommerer C; Hinkel UP; Hoffmann O; Zeier M; Schwenger V
J Hypertens; 2008 Nov; 26(11):2213-9. PubMed ID: 18854763
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic monitoring of cyclosporine A by NFAT-regulated gene expression and the relationship with infectious complications in pediatric renal transplant recipients.
Billing H; Giese T; Sommerer C; Zeier M; Feneberg R; Meuer S; Tönshoff B
Pediatr Transplant; 2010 Nov; 14(7):844-51. PubMed ID: 20602720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
